View verification details in our COA Library
Characterization of the human endothelial nitric-oxide synthase promoter
We wanted to resolve the lack of consensus with our work. Analyzing de-identified patient data collected from December 2017 through December 2024 across 12 databases managed by the Observational Health Data Sciences and Informatics (OHDSI) network-an international and interdisciplinary collaborative of researchers and observational health databases the researchers followed the health outcomes of adults with type 2 diabetes who had been prescribed semaglutide (227,971), dulaglutide (68,588), exenatide (5,460), empagliflozin (252,356), sitagliptin (100,083) or glipizide (213,515) for the first time
Sources and further reading Ahmann AJ et al
SGLT1, sodium/glucose transporter 1
2026 Jan 31;19:17562864251408269